Glucocorticoids and mepolizumab in eosinophilic asthma. by Bel, E, Ortega, H, Pavord, I

Biomarkers for severe eosinophilic asthma. by Yancey, S, Keene, O, Albers, F, Ortega, H, Bates, S, Bleecker, E, Pavord, I

Real-World Effectiveness of Mepolizumab in Patients with Severe Asthma: An Examination of Exacerbations and Costs by Llanos JP, Ortega H, Bogart M, Packnett ER, Manjelievskaia J, Bell CF, Hahn B

Get full text

Real-world characteristics and disease burden of patients with asthma prior to treatment initiation with mepolizumab or omalizumab: a retrospective cohort database study by Llanos JP, Bell CF, Packnett E, Thiel E, Irwin DE, Hahn B, Ortega H

Get full text

Health characteristics of patients with asthma, COPD and asthma–COPD overlap in the NHANES database by Llanos JP, Ortega H, Germain G, Duh MS, Lafeuille MH, Tiggelaar S, Bell CF, Hahn B

Get full text

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. by Ortega, H, Yancey, S, Mayer, B, Gunsoy, N, Keene, O, Bleecker, E, Brightling, C, Pavord, I

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. by Bel, E, Wenzel, SE, Thompson, P, Prazma, C, Keene, O, Yancey, S, Ortega, H, Pavord, I

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. by Pavord, I, Korn, S, Howarth, P, Bleecker, E, Buhl, R, Keene, O, Ortega, H, Chanez, P

Burden of disease associated with a COPD eosinophilic phenotype by Ortega H, Llanos JP, Lafeuille MH, Germain G, Duh MS, Bell CF, Sama SR, Hahn B

Get full text

The GOLMePsA study protocol: an investigator-initiated, double-blind, parallel-group, randomised, controlled trial of GOLimumab and methotrexate versus methotrexate in early diagno... by De Marco, G, Helliwell, P, McGonagle, D, Emery, P, Coates, L, Hensor, E, Marzo-Ortega, H

Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma by Yancey, S, Ortega, H, Keene, O, Mayer, B, Gunsoy, N, Brightling, C, Bleecker, E, Haldar, P, Pavord, I

Improving the treatment of ankylosing spondylitis in the UK. by Keat, A, Gaffney, K, Marzo-Ortega, H, Cornell, T, MacKay, K, Skerrett, J, Van Rossen, L, Wordsworth, B

BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology. by Keat, A, Barkham, N, Bhalla, A, Gaffney, K, Marzo-Ortega, H, Paul, S, Rogers, F, Somerville, M, Sturrock, R, Wordsworth, P

Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: a post-hoc analysis of the MAXIMISE trial by Baraliakos, X, Pournara, E, Gossec, L, Mease, P, White, R, O’Brien, E, Schulz, B, Marzo Ortega, H, Coates, LC

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis by Haldar, P, Brightling, C, Singapuri, A, Hargadon, B, Gupta, S, Monteiro, W, Bradding, P, Green, R, Wardlaw, A, Ortega, H, Pavord, I

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. by Haldar, P, Brightling, C, Singapuri, A, Hargadon, B, Gupta, S, Monteiro, W, Bradding, P, Green, R, Wardlaw, A, Ortega, H, Pavord, I

Mepolizumab treatment in patients with severe eosinophilic asthma. by Ortega, H, Liu, M, Pavord, I, Brusselle, G, FitzGerald, J, Chetta, A, Humbert, M, Katz, L, Keene, O, Yancey, S, Chanez, P

Brief report: group 3 innate lymphoid cells in human enthesis by Cuthbert, R, Fragkakis, E, Dunsmuir, R, Li, Z, Coles, M, Marzo-Ortega, H, Giannoudis, P, Jones, E, El-Sherbiny, Y, McGonagle, D

Imaging of the Achilles tendon in spondyloarthritis: a comparison of ultrasound and conventional, short and ultrashort echo time MRI with and without intravenous contrast by Hodgson, R, Grainger, A, O'Connor, P, Evans, R, Coates, L, Marzo-Ortega, H, Helliwell, P, McGonagle, D, Emery, P, Robson, M

Imaging of the Achilles tendon in spondyloarthritis: a comparison of ultrasound and conventional, short and ultrashort echo time MRI with and without intravenous contrast. by Hodgson, R, Grainger, A, O'Connor, P, Evans, R, Coates, L, Marzo-Ortega, H, Helliwell, P, McGonagle, D, Emery, P, Robson, M